PHOENIX, March 3, 2020 -- Taking estradiol within 6 years after the onset of menopause may help prevent atherosclerosis, plaque buildup in artery walls, from progressing; however, starting estradiol therapy ten years after menopause did not have similar benefits, according to preliminary research presented at the American Heart Association's Epidemiology and Prevention | Lifestyle and Cardiometabolic Health Scientific Sessions 2020. The EPI Scientific Sessions, March 3-6 in Phoenix, is a premier global exchange of the latest advances in population-based cardiovascular science for researchers and clinicians.
Estradiol is a female sex hormone and a form of estrogen that is often prescribed to treat the symptoms of menopause and to prevent osteoporosis.
"Atherosclerosis is a major cause of heart disease, and cholesterol accumulation in the arterial wall is the predominant characteristic of atherosclerosis," said lead study author Roksana Karim, Ph.D., M.B.B.S., an associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California in Los Angeles. "Our results show that estradiol initiated earlier in menopause reduces atherosclerosis and appears to do so by directly reducing cholesterol accumulation in the arterial wall."
Karim and colleagues analyzed findings from the Early versus Late Intervention Trial with Estradiol (ELITE), a study of 643 healthy, postmenopausal women who were divided into 4 groups: participants in group 1 and 2 were randomized to 1 mg daily of estradiol or to a placebo pill within six years after the onset of menopause; and those in groups 3 and 4 were randomized to estradiol or to placebo more than a decade after menopause. All study participants took estradiol or placebo daily for an average of five years. The study's initial findings, published in 2016, indicated that women starting hormone therapy earlier in menopause experienced less progression of artery wall thickening, compared to those who started the hormone therapy later or who received the placebo.
When the researchers looked further into estradiol's impact on heart health by analyzing cholesterol, or lipids, in the arterial wall, they found the rate of atherosclerosis progression among early estradiol users was less than half, compared to the women taking placebo who had gone through menopause within the last six years.
Estradiol did not have this benefit among the women who started the hormone therapy 10 years or more after the onset of menopause. Cholesterol in the arterial wall and atherosclerosis progressed similarly for both the women in the placebo group and those who started estradiol therapy a decade after menopause.
"Our results show that starting estradiol soon after the onset of menopause may result in fewer cholesterol deposits in the arteries, compared to women starting estradiol much later," said Karim.
"The American Heart Association does not recommend hormone replacement therapy after the onset of menopause to prevent heart disease. Although some studies, like this one, show benefits, we are still seeing other trials with different outcomes. Because of that, estrogen replacement therapy should be used only to alleviate the symptoms of menopause," said Suzanne Steinbaum, D.O., an American Heart Association volunteer expert, an attending cardiologist and director of Women's Heart Health of Northwell Lenox Hill Hospital, and senior faculty at Mount Sinai Hospital in New York City.
Co-authors of the study are Howard N. Hodis, M.D.; Naoko Kono, M.P.H.; Yanji Li, M.D.; Mingzhu Yan, M.D.; Frank Stanczyk, Ph.D.; and Wendy J. Mack, Ph.D. Author disclosures are in the abstract.
The National Institute of Aging of the National Institutes of Health funded the study.
Downloadable multimedia related to this news release are on the right column of the link https:/
American Heart Association News Release: Worsening migraines with hormone replacement linked to stroke risk
Women Have a Higher Risk of Stroke
For more news from AHA EPI Lifestyle Conference 2020, follow us on @HeartNews #EPILifestyle20.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect Association policy or position. The Association makes no representation or warranty as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at https:/
The American Heart Association's EPI | LIFESTYLE 2020 Scientific Sessions is the world's premier meeting dedicated to the latest advances in population-based science and will be held March 3-6 in Phoenix, Arizona. The four-day conference will feature nearly 600 compelling scientific presentations to promote the development and application of translational and population science to prevent heart disease and stroke and foster cardiovascular health. The theme of this year's conference is Promoting Cardiovascular Health Across the Lifespan: How Do We Live Healthier, Longer? and is presented in collaboration with the Council on Lifestyle and Cardiometabolic Health and the Council on Epidemiology and Prevention. Follow the conference on Twitter at #EPILifestyle20.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public's health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.